We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Supernus Pharmaceuticals unveiled topline results from two phase 3 studies of children with attention deficit hyperactivity disorder but failed to wow investors worried about how its nonstimulant treatment would take on already-established generics.....